Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Closes $210M Sale of BioReliance to Avista Capital

NEW YORK (GenomeWeb News) - Invitrogen has closed the $210 million sale of its BioReliance unit to Avista Capital Partners as part of its plans to better organize some of its acquisitions and streamline its focus, the company said today.
As GenomeWeb Daily News reported on Feb. 14, Invitrogen’s CEO and chairman Greg Lucier agreed to sell the biological services unit to Avista in an effort to focus on its platform of scientific technologies.
Lucier today reiterated that the move followed a thorough portfolio review, after which the company decided to unload the services business to concentrate on its tools and technologies.
The decision to sell BioReliance came at the same time Invitrogen posted a 300 percent decline in 2006 fourth quarter net income compared with the same period in 2005.
Avista named Tim Derrington, who was BioReliance’s general manager under Invitrogen, to take over as CEO of the Rockville, Md.-based biological services company.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.